Related Experiment Video
Updated: May 19, 2026
05:46
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Uveal melanoma dormancy: an acceptable clinical endpoint?
Paula L Blanco1, Li Anne Lim, Cristina Miyamoto
1Henry C. Witelson Ophthalmic Pathology Laboratory and Registry, Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada. paula.blanco@mail.mcgill.ca
Melanoma Research
|August 17, 2012
Summary
Uveal melanoma survival is unchanged despite early detection. This rare cancer
Area of Science:
- Ophthalmology
- Oncology
- Cancer Biology
Background:
- Uveal melanoma (UM) is a rare, aggressive eye cancer.
- Early detection has improved treatment but not survival rates.
- Mortality remains high due to late-stage metastatic disease.
Purpose of the Study:
- To review current knowledge on uveal melanoma biology.
- To discuss novel therapeutic targets for uveal melanoma.
- To understand the mechanisms behind delayed metastasis.
Main Methods:
- Literature review of uveal melanoma research.
- Analysis of diagnostic and treatment advancements.
- Exploration of tumor dormancy and metastasis theories.
Main Results:
- Early detection improves local control but not overall survival.
- Metastasis is often present at diagnosis, leading to late mortality.
- Circulating tumor cells suggest early dissemination.
Conclusions:
- Life expectancy in uveal melanoma is independent of primary tumor control.
- Tumor dormancy is a key factor in delayed metastasis.
- Understanding UM biology is crucial for developing effective therapies.
